Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is marked by the abnormal production of amyloid-beta (Aβ) fibrils, a key biomarker for diagnosis and illness monitoring. Advanced microfluidic devices, such as brain-on-a-chip (BoC), are innovative preclinical tools with the potential to revolutionize AD early diagnosis and treatment. However, existing BoCs face limitations, including challenge...